transgene mit potenzial - 500 Beiträge pro Seite

[okidoki85]

hey leute,

was haltet ihr von transgene? wurde vom aktionär empfohlen, aber risikoreich. Kursziel 12 euro. das wären über 30 %!!

[_budgie]

ohhh, da hattest du mich missvertanden. ich meinte nur, dass mir aufgefallen ist, dass GENERELL im WO sehr viel gepusht wird. aber viropharm finde ich gut behandelt, vor allem scheinst du hier die beruhigende hand im thread zu sein.

WEITER SO!!!

[_budgie]

uppss, sorry war falscher thread

[_budgie]

nichtsdestotrotz, scheint transgene sehr interssant zu sein - einfach noch nicht entdeckt.

ich werde mal ein paar infos sammeln und posten.

[_budgie]

tja, kaum wurde transgene im "der aktionär tv" schon habe sich ein paar pfiffige sie sich geschnappt. (auf n24 von 14.30 bis 15.00 uhr)






trotzdem sollte sie auch richtig analysiert werden - auf jungs!!

[_budgie]

http://www.transgene.fr/us/

Mission Statement

Transgene is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases.

Business Strategy

Transgene`s business strategy is to develop therapeutic vaccines against cancer and infectious diseases based on its broad technology platform for gene delivery and its access to genes of potential therapeutic interest. Transgene implements this strategy in three different ways :

by developing vaccines and products in specific indications and partnering with pharmaceutical companies for later stage development ;

by independently developing and commercializing vaccines and products for certain special markets ;

by licensing vector technologies to companies with proprietary genes for short and medium term revenues.


Pipeline

Beiden vielversprechensten kandidaten sind: MVA-MUC1-IL2 und MVA-HPV-IL2.

Cancer Vaccine
Product : MVA-MUC1-IL2 (TG4010)
Indications : MUC1-positive tumors
Development Status : Phase II

Cancer Vaccine
Product : MVA-HPV-IL2 (TG4001)
Indications : Human Papilloma Virus-associated pathologies : cervical cancer and pre-cancerous lesions
Development Status : End of Phase II

Immune Enhancement Gene Therapy
Product : Ad-IFNγ(TG1042)
Indications : Primary and metastatic solid tumors e.g. cutaneous lymphoma and hepatocellular carcinoma
Development Status : Phase II

Immune Enhancement Gene Therapy
Product : Ad-IL2 (TG1024)
Indications : Primary and metastatic solid tumors
Development Status : Phase I/II

[_budgie]

News vom 21.07.2005 06:07

Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene`s Proprietary Technology

STRASBOURG, France, July 21 /PRNewswire-FirstCall/ -- Transgene (Nachrichten) (Eurolist Paris : FR0005175080; Nasdaq: TRGNY) announced today that Merck&Co. (Nachrichten) has met a clinical development milestone for a vaccine candidate constructed with Transgene`s proprietary homologous recombination technology. This technology enables the highly efficient and fast generation of recombinant viral vectors, in particular adenovirus vectors, which can be used in a broad range of applications, including recombinant vaccines and in vitro diagnostics.

Transgene granted Merck a non-exclusive license for this technology in January 2003 and expects to receive, in addition to the initial license fee and annual maintenance fees, milestone payments based on the further development of products by Merck, as well as royalties on any marketed products.

"The initiation of a Phase I trial triggers the first clinical milestone payment under the license agreement signed between Merck and Transgene," said Philippe Archinard, Chief Executive Officer of Transgene. "We are pleased that Merck is making further progress towards developing vaccines using our proprietary technology."

Transgene, based in Strasbourg, France is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has a broadportfolio of clinical stage immunotherapy drugs, technologies available for out-licensing and viral vectors bio-manufacturing capacities.

This press release contains forward-looking statements referring to the further development and eventual marketing of Transgene proprietary technology, as well as to the receipt by Transgene of future milestone and royalty payments related thereto. However, as is the case with all biopharmaceutical products and technology under development, results from clinical testing may not show favourable outcomes, and there is no certainty that technology under development will ever demonstrate adequate medical efficacy or achieve regulatory approval or commercial use. As a result, the receipt by Transgene of further milestone payments and eventually royalty payments for marketed products is uncertain. For a description of the principal risks facing the successful clinical and commercial development of Transgene`s products and technology, see Transgene`s Annual Report on Form 20-F and its other reports on file with the U.S. Securities and Exchange Commission.

[_budgie]

wer kann etwas zu dieser chart erzählen - 6 monate. ist doch ganz bestimmt etwas für unsere chartanalysten!!